{"id":8232,"date":"2026-03-24T10:29:24","date_gmt":"2026-03-24T09:29:24","guid":{"rendered":"http:\/\/ic-steiermark.at.w02242c6.kasserver.com\/success_stories\/ai-powered-blood-diagnostics-from-styria-with-a-global-vision\/"},"modified":"2026-11-02T13:31:30","modified_gmt":"2026-11-02T12:31:30","slug":"ai-powered-blood-diagnostics-from-styria-with-a-global-vision","status":"publish","type":"success_stories","link":"https:\/\/www.ic-steiermark.at\/en\/success_stories\/ai-powered-blood-diagnostics-from-styria-with-a-global-vision\/","title":{"rendered":"AI-powered Blood Diagnostics from Styria with a Global Vision"},"content":{"rendered":"
\n
\n \n
\n \n \"\"\n <\/a>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n \n
\n
\n

The Styrian company RobotDreams<\/strong> is developing a highly innovative, AI-powered diagnostic platform with a clear vision: AI-based blood diagnostics should become the global standard for almost all clinical pictures in the future. At its core is a powerful, trained AI model that differentiates clinical conditions with exceptional accuracy \u2013 with AUROC values of over 90%. <\/p>\n

The first diagnostic module focuses on predicting Acute Coronary Syndrome (ACS) \u2013 one of the most common and critical causes of hospital admissions worldwide. Further modules for the early detection of heart failure (HF) and coronary artery disease (CAD) are already under development. In the long term, RobotDreams plans to expand into other specialties such as nephrology, hepatology, neurology, and pulmonology \u2013 with the goal of fundamentally transforming laboratory medicine. <\/p>\n<\/div>\n <\/div>\n

\n

Precision Meets Clinical Expertise<\/strong><\/p>\n

The technology combines state-of-the-art machine learning with in-depth clinical expertise. Blood data is analyzed using AI to identify diseases early, quickly, and precisely \u2013 a crucial advantage in emergency and preventive medicine. <\/p>\n

Parallel to technological development, RobotDreams is intensively working on patent applications, clinical studies, as well as CE marking and IVDR certification. These regulatory steps are essential to meet the highest quality and safety standards and to ensure sustainable market launch in the European healthcare sector. <\/p>\n<\/div>\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n \n \"\" <\/a>\n <\/div>\n
\n \n \"\" <\/a>\n <\/div>\n
\n \n \"\" <\/a>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n
\n
\n
\n
\n \n
\n
\n

Strategic Partnerships as a Growth Engine<\/strong><\/p>\n

To accelerate clinical validation, regulatory processes, and commercialization, RobotDreams collaborates with international industry leaders such as Roche, Novartis, Sysmex, and Siemens Healthineers.<\/p>\n

These strategic partnerships combine industrial expertise and create the foundation for rapid scaling into international markets.<\/p>\n<\/div>\n <\/div>\n

\n <\/div>\n <\/div>\n <\/div>\n\n <\/div>\n <\/div>\n <\/div>\n
\n
\n \n
\n \n
\n
\n
\n
\n \"\" <\/div>\n
\n

“We develop technology that saves lives, drastically reduces waiting times in the emergency room, and noticeably lowers costs. This is exactly what medical progress in the 21st century looks like. DESIRE has enabled us to pursue this ambition at full speed.”<\/p>\n<\/div>\n

Ulrich Weigelt, Co-Founder & CEO<\/p>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n <\/div>\n

\n
\n
\n
\n \n
\n
\n

Tailwind from DESIRE \u2013 with ICS as Lead Partner<\/strong><\/h3>\n

RobotDreams received a decisive boost from the EU project DESIRE, in which ICS acted as the lead partner. All support services within the framework of the project were implemented by the DESIRE team at ICS \u2013 and it was precisely here that the strategic added value emerged, which makes all the difference for a DeepTech company in a sensitive development phase. <\/p>\n

Through DESIRE, RobotDreams was able to:<\/p>\n